Genmab

Genmab’s €400 m acquisition of Merus adds petosemtamab, a Breakthrough Therapy bispecific antibody for head‑and‑neck cancer, boosting its oncology pipeline and potential revenue.

Genmab’s epcoritamab shows 70‑80% response in follicular lymphoma, with a US NPV of $1.1 B—boosting its value, pricing strategy, and M&A appeal.

Genmab’s Phase 3 EPCORE FL‑1 data show epcoritamab boosts response rates by 20% in relapsed follicular lymphoma, hinting at high market value and regulatory upside.

Genmab’s subcutaneous bispecific epcoritamab shows >70 % response and durable survival in first‑line diffuse large B‑cell and follicular lymphoma, offering a safer, fixed‑duration alternative to anthracyclines.

Genmab A/S, a Danish biotech company, is poised for commercial success with its bispecific antibody Rina-S, which has shown impressive early-stage clinical results in advanced endometrial cancer and has received Breakthrough Therapy Designation from…